Spondyloarthritis & psoriatic arthritis
Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2–5 and MAXIMISE studies
Authors' conclusion
Patients with PsA and hyperuricaemia have different clinical characteristics from patients with PsA and normouricaemia.
Study context
- Population
- Patients with PsA treated with secukinumab in the FUTURE 2–5 and MAXIMISE studies
- Comparison
- Hyperuricaemia vs normouricaemia in PsA patients treated with secukinumab
- Outcome
- Response to secukinumab by baseline uricaemia status
- Follow-up
- Up to week 52
Methodological detailspooled data, stratified by baseline serum uric acid (SUA) (threshold 360 µmol/L), sensitivity analysis at SUA thresholds 300 µmol/L and 420 µmol/L
- Pooled data
- Stratified by baseline SUA (threshold 360 µmol/L)
- Sensitivity analysis at SUA thresholds 300 µmol/L and 420 µmol/L
Pooled result
As reported in the abstract
- Similar proportions in normouricaemic and hyperuricaemic cohorts achieved ACR responses, resolution of enthesitis and dactylitis, inhibition of structural damage progression and improvement in health-related quality of life across all secukinumab doses
Further pooled results
Baseline characteristics
- Hyperuricaemic patients mostly male, higher prevalence of hypertension, more clinical dactylitis, more psoriasis and more severe skin disease vs normouricaemic
Original publication
Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2–5 and MAXIMISE studies. RMD Open. Published 9 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →